evaluate the pharmaceuticals and biotechnology company novo nordisk on glp-1's Nordisk, GLP-1s, Alzheimer's: Readout Newsletter GLP-1s Are Just Getting Started:

Cancer risks decline in general when patients lose weight, whether that is through diet or bariatric surgery, for example

Getting popular peptides reclassified as category one would be a big deal, Husain says

WHO and EMA Warnings About Semaglutide and NAION In June 2025, the World Health Organization alerted healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide medications, including Ozempic, Rybelsus, and Wegovy

Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach

One placebo-controlled study examined the effect of lipoic acid on the visual capability of 80 participants of whom 12 had type 1 diabetes, 48 had type 2 diabetes, and 20 were diabetes-free

Very few actually do both effectively